Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

NPJ Precis Oncol. 2021 Sep 17;5(1):86. doi: 10.1038/s41698-021-00222-y.

C B Westphalen¹, M G Krebs², C Le Tourneau^{3

4

5}, E S Sokol⁶, S L Maund⁷, T R Wilson⁷, D X Jin⁶, J Y Newberg⁶, D Fabrizio⁶, L Veronese⁸, M Thomas⁸, F de Braud^{9

10}

¹ Comprehensive Cancer Center Munich & Department of Medicine III, University Hospital, LMU Munich, Munich, Germany. cwestpha@med.lmu.de.
² Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
³ Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France, Saint-Cloud, France.
⁴ INSERM U900 Research Unit, Saint-Cloud, France.
⁵ Paris-Saclay University, Paris, France.
⁶ Foundation Medicine Inc., Cambridge, MA, USA.
⁷ Genentech Inc., South San Francisco, CA, USA.
⁸ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁹ Department of Medical Oncology and Haematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
¹⁰ School of Specialisation in Medical Oncology, University of Milan, Milan, Italy.

No abstract available

Publication types